• Skip to primary navigation
  • Skip to content
  • Skip to primary sidebar
  • Skip to footer

BerGenBio

Selective AXL inhibitors

Header Right

Main navigation

  • About BerGenBio
    • About BerGenBio
    • Management Team
    • Board of Directors
    • Partners
  • Pipeline
    • Pipeline overview
    • bemcentinib | NSCLC
    • bemcentinib | TNBC
    • bemcentinib | Melanoma
    • bemcentinib | AML
    • BGB149
    • BGB601
    • Discovery
    • Publications
  • Media Centre
    • News
    • Events
    • Media Contacts
  • Investors
    • Share Information
    • Largest Shareholders
    • Stock Exchange Notices
    • Presentations
    • Financial Reports
    • Financial Calendar
    • Analysts
    • General Meetings
    • Corporate Governance
    • IR Contacts
  • Contact
Home  /  News

Category: News

2018201720162015

BerGenBio ASA: Results for the Fourth Quarter and Full Year 2018

February 12, 2019

Important progress made in 2018: PoC for bemcentinib reported in multiple cancer indications AML/MDS and…

Read More

BerGenBio ASA: Invitation to Fourth Quarter and Full Year 2018 Results Presentation and Webcast

February 5, 2019

Bergen, Norway, 05 February 2019 - BerGenBio ASA (OSE:BGBIO), will announce its results for the…

Read More

BerGenBio announces start of phase I trial evaluating ADCT-601, a novel anti-AXL ADC, in patients with advanced solid tumours

January 21, 2019

ADCT-601 uses a proprietary AXL antibody developed by BerGenBio and licensed to ADC Therapeutics for…

Read More

BerGenBio Announces Start of Phase I Trial Evaluating First-in-Class Anti-AXL Antibody BGB149

January 9, 2019

BGB149 is the first therapeutic anti-AXL monoclonal antibody to enter clinical development BGB149 is BerGenBio’s…

Read More

BerGenBio to present company overview at Biotech Showcase 2019 during annual J.P. Morgan Conference in San Francisco

January 8, 2019

Bergen, Norway, Jan 8th 2019 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company focused on…

Read More

BerGenBio Announces Start of Phase II Investigator Initiated Trial Evaluating Selective AXL Inhibitor Bemcentinib in high-risk MDS

January 4, 2019

Phase II monotherapy study of bemcentinib in high-risk MDS & AML Will enrol up to…

Read More
  • Page 1
  • Page 2
  • Page 3
  • …
  • Page 15
  • NEXT

Primary Sidebar

  • Media Centre
  • News
  • Events
  • Media Contacts

News Subscription

Please remember to confirm your email by clicking on the link provided in the subscription confirmation email.

We will save your name and email address with the sole purpose of sending information regarding our latest news and events. By subscribing to BerGenBio’s newsletter you consent to our Privacy Policy and Terms of Use.

Footer

Key Information

  • Pipeline
  • Investors
  • News
  • Presentations
  • Management Team

Useful Information

  • Privacy Policy
  • Terms of Use
  • Site Map

Get In Touch

BerGenBio ASA
Company registration number 992 219 688

Jonas Lies vei 91, 5009 Bergen, Norway

www.bergenbio.com

+ 47 559 61 159 (general) + 47 535 01 564 (urgent medical enquiries)

Copyright © 2017 BerGenBio ASA. All right reserved. Designed by Utopian Designs